Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | TACR3 | P29371 | 8/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693312 | 0.91 | KDM4E (0.42) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL8275065 | 0.88 | KDM4E (0.48) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL13123350 | 0.88 | KDM4E (0.48) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL14094641 | 0.85 | KDM4E (0.53) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL4981257 | 0.82 | CYP3A4 (0.45) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL8354909 | 0.82 | CYP3A4 (0.45) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL5693315 | 0.82 | KDM4E (0.41) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL6402575 | 0.82 | KDM4E (0.41) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL9971085 | 0.82 | KDM4E (0.48) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 | |
| SCHEMBL375146 | 0.82 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1PLA2G2ATACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878722-B2 | Substituted cycloalkyl P1′ hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | HAVCR2, ANPEP, ENPEP | KDM4E 4299/4885SMN1; SMN2 4827/4885ALDH1A1 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.